Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome
Objectives: Intravesical Bacillus Calmette-Guérin (BCG) treatment for superficial bladder cancer is interrupted in approximatively 8% of cases as a result of complications. The objective is to report the severe related complications of Bacillus Calmette-Guérin (BCG) following an intravesical instill...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-05-01
|
Series: | Journal of Clinical Tuberculosis and Other Mycobacterial Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405579420300073 |
id |
doaj-92737d143b1c4a3d8b0067747de20005 |
---|---|
record_format |
Article |
spelling |
doaj-92737d143b1c4a3d8b0067747de200052020-11-25T02:25:24ZengElsevierJournal of Clinical Tuberculosis and Other Mycobacterial Diseases2405-57942020-05-0119Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcomeR. Waked0J. Choucair1N. Chehata2E. Haddad3G. Saliba4Department of Infectious Diseases, Faculty of Medicine, Saint Joseph University, Damascus street, PO BOX 11-5076, Riad El Solh, Beirut 1107 2180, Lebanon; Corresponding author.Coordinator of the Infectious Diseases department, Saint Joseph University, Beirut, LebanonDepartment of Infectious Diseases, Faculty of Medicine, Saint Joseph University, Damascus street, PO BOX 11-5076, Riad El Solh, Beirut 1107 2180, LebanonDepartment of Infectious Diseases, Faculty of Medicine, Saint Joseph University, Damascus street, PO BOX 11-5076, Riad El Solh, Beirut 1107 2180, LebanonDepartment of Infectious Diseases, Faculty of Medicine, Saint Joseph University, Damascus street, PO BOX 11-5076, Riad El Solh, Beirut 1107 2180, LebanonObjectives: Intravesical Bacillus Calmette-Guérin (BCG) treatment for superficial bladder cancer is interrupted in approximatively 8% of cases as a result of complications. The objective is to report the severe related complications of Bacillus Calmette-Guérin (BCG) following an intravesical instillation for bladder tumor encountered at our institution for the past 5 years. Methods: Medical records of a tertiary teaching hospital, located in Beirut, Lebanon, were retrospectively analyzed from June 2014 to June 2019 searching for severe related complications of BCG. A comprehensive review of articles on this subject was conducted. Results: The incidence of severe systemic adverse events related to BCG instillation was 1.5% (5 out of 332 patients). A total of five patients were found to have a severe BCG related complication, with fever, chills, and irritative urinary signs being the most frequent symptoms. All patients received antituberculosis therapy (Isoniazid, Rifampin and Ethambutol). Two were put on add-on corticosteroids. Three patients had a computed tomography scan image in favor of an infection. Two patients had a favorable outcome, three patients died. Conclusion: BCG severe adverse events were mostly seen in patients with a traumatic instillation. Treatment used at our institution was similar to most cases reported in the literature. A standardized diagnostic and treatment approach should be implemented to help physicians tackle these life-threatening complications.http://www.sciencedirect.com/science/article/pii/S2405579420300073Mycobacterial infectionIntravesical Bacillus Calmette-GuérinBacillus Calmette-GuerinUrothelial bladder cancerSevere complicationTreatment protocol |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
R. Waked J. Choucair N. Chehata E. Haddad G. Saliba |
spellingShingle |
R. Waked J. Choucair N. Chehata E. Haddad G. Saliba Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Mycobacterial infection Intravesical Bacillus Calmette-Guérin Bacillus Calmette-Guerin Urothelial bladder cancer Severe complication Treatment protocol |
author_facet |
R. Waked J. Choucair N. Chehata E. Haddad G. Saliba |
author_sort |
R. Waked |
title |
Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome |
title_short |
Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome |
title_full |
Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome |
title_fullStr |
Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome |
title_full_unstemmed |
Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome |
title_sort |
intravesical bacillus calmette-guérin (bcg) treatment's severe complications: a single institution review of incidence, presentation and treatment outcome |
publisher |
Elsevier |
series |
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases |
issn |
2405-5794 |
publishDate |
2020-05-01 |
description |
Objectives: Intravesical Bacillus Calmette-Guérin (BCG) treatment for superficial bladder cancer is interrupted in approximatively 8% of cases as a result of complications. The objective is to report the severe related complications of Bacillus Calmette-Guérin (BCG) following an intravesical instillation for bladder tumor encountered at our institution for the past 5 years. Methods: Medical records of a tertiary teaching hospital, located in Beirut, Lebanon, were retrospectively analyzed from June 2014 to June 2019 searching for severe related complications of BCG. A comprehensive review of articles on this subject was conducted. Results: The incidence of severe systemic adverse events related to BCG instillation was 1.5% (5 out of 332 patients). A total of five patients were found to have a severe BCG related complication, with fever, chills, and irritative urinary signs being the most frequent symptoms. All patients received antituberculosis therapy (Isoniazid, Rifampin and Ethambutol). Two were put on add-on corticosteroids. Three patients had a computed tomography scan image in favor of an infection. Two patients had a favorable outcome, three patients died. Conclusion: BCG severe adverse events were mostly seen in patients with a traumatic instillation. Treatment used at our institution was similar to most cases reported in the literature. A standardized diagnostic and treatment approach should be implemented to help physicians tackle these life-threatening complications. |
topic |
Mycobacterial infection Intravesical Bacillus Calmette-Guérin Bacillus Calmette-Guerin Urothelial bladder cancer Severe complication Treatment protocol |
url |
http://www.sciencedirect.com/science/article/pii/S2405579420300073 |
work_keys_str_mv |
AT rwaked intravesicalbacilluscalmetteguerinbcgtreatmentsseverecomplicationsasingleinstitutionreviewofincidencepresentationandtreatmentoutcome AT jchoucair intravesicalbacilluscalmetteguerinbcgtreatmentsseverecomplicationsasingleinstitutionreviewofincidencepresentationandtreatmentoutcome AT nchehata intravesicalbacilluscalmetteguerinbcgtreatmentsseverecomplicationsasingleinstitutionreviewofincidencepresentationandtreatmentoutcome AT ehaddad intravesicalbacilluscalmetteguerinbcgtreatmentsseverecomplicationsasingleinstitutionreviewofincidencepresentationandtreatmentoutcome AT gsaliba intravesicalbacilluscalmetteguerinbcgtreatmentsseverecomplicationsasingleinstitutionreviewofincidencepresentationandtreatmentoutcome |
_version_ |
1724851533847199744 |